Insulet Corp stock slides 9.70% and underperforms competitors

7 articles · Updated · MarketWatch · May 6

Shares closed at $151.28 on Wednesday, their third straight daily loss, as the S&P 500 rose 1.46% and the Dow gained 1.24%.
Insulet lagged peers including DexCom, which rose 1.48%, while Eli Lilly slipped 0.18% and Johnson & Johnson fell 0.41% in the broadly positive session.
The stock finished 57.37% below its 52-week high of $354.88 reached on 20 November, while trading volume jumped to 4.4 million against a 50-day average of 1.0 million.

After a major recall crushed its stock, is Insulet a catastrophic failure or a once-in-a-lifetime investment?

With insulin pumps leaking and alarms failing, can Insulet regain the trust of the diabetes community it serves?